Cigna
LS - DIS - 77636
PO Box 3050
Easton PA 18043-3050

May 28, 2020

Ajani Nimmagadda, MD
Managing Medical Director

WILLIAM H ISACOFF MD
10921 WILSHIRE BLVD STE 505
LOS ANGELES CA 90024-4001

Re: Expansion of Specialty Medical Injectables with Reimbursement Restriction, effective September 1, 2020

Dear WILLIAM H ISACOFF MD,

Our reimbursement restriction guidelines for certain specialty medications originally went into effect on May 1, 2018. These guidelines, now called the Specialty Medical Injectables with Reimbursement Restriction guidelines, state that certain injectables must be dispensed and their claims must be submitted by a Cigna-contracted specialty pharmacy.

For new prior authorizations obtained on or after September 1, 2020, we will expand the Specialty Medical Injectables with Reimbursement Restriction list to include additional specialty medical injectables. The updated list is available on the Cigna for Health Care Professionals website (CignaforHCP.com > Resources > Reimbursement Policies and Payment Policies> Precertification Policies > Specialty Medical Injectables with Reimbursement Restriction).

Cigna may grant approval for coverage of an initial dose to a facility when medical necessity is met to allow arrangements to obtain the drug from a Cigna-contracted specialty pharmacy.

What this means to you
Cigna will no longer reimburse facilities directly for the drugs that are included in the Specialty Medical Injectables with Reimbursement Restriction list. Please note that facilities cannot bill patients with Cigna-administered coverage for the cost of these injectables when they are not obtained from a specialty pharmacy in the Cigna network.

Additional information
As previously mentioned, the updated Specialty Medical Injectables with Reimbursement Restriction list is available on the Cigna for Health Care Professionals website. We recommend you review this list frequently as it is subject to change. Specialty medical injectables may be added upon U.S. Food and Drug Administration (FDA) approval.

Later this year, we will update the Cigna Reference Guide for physicians, hospitals, ancillaries, and other providers to include additional information about the Specialty Medical Injectables with Reimbursement Restriction guidelines. You can access this guide by logging in to the Cigna for Health Care Professionals website (CignaforHCP.com > Resources > Reference Guides).

If you have any questions, please call Cigna Customer Service at **800.88Cigna (882.4462)**.

Thank you for the care you provide our customers.

Sincerely,

Dr. Ajani Nimmagadda
Managing Medical Director

964771391301

LIST OF SPECIALTY MEDICAL INJECTABLES WITH REIMBURSEMENT RESTRICTION

For Facilities

Updated June 2020

Per our Specialty Medical Injectables with Reimbursement Restriction guidelines, certain specialty medical injectables must be dispensed and their claims must be submitted by a specialty pharmacy with which Cigna has a reimbursement arrangement. We will not reimburse facilities that purchase these injectables directly from specialty pharmacies, manufacturers, or wholesalers. These guidelines were formerly known as the Limited Distribution Drugs with a Reimbursement Restriction.

Additional information about these guidelines is available in the Cigna Reference Guide for physicians, hospitals, ancillaries, and other providers. To access this guide, log in to the Cigna for Health Care Professionals website (CignaforHCP.com > Resources > Reference Guides).

Important: Please read

1. The Specialty Medical Injectables with Reimbursement Restriction list has three categories:
    - Gene therapy injectables
    - Specialty medical injectables
    - Oncology injectables

2. The Specialty Medical Injectables with Reimbursement Restriction list is subject to change without prior notice.

The following tables detail the affected drugs.

Gene Therapy Injectables[1]			
Healthcare Common Procedure Coding System (HCPCS) code(s)	**Name**	**Contracted specialty pharmacy**	**Date prior authorization obtained (on or after)**
J3398	LUXTURNA® (voretigene neparvovec-rzyl)	Accredo	May 1, 2018
C9399, J3490, J3590, J9999	ZOLGENSMA® (onasemnogene abeparvovec-xioi)	Accredo	May 24, 2019
C9399, J3490, J3590, J9999	ADSTILADRIN® (nadofaragene firadenovec)	Cigna contracted specialty pharmacy	Following U.S. Food and Drug Administration approval

1. These drugs, which Cigna has designated as gene therapy products, are included in the Cigna Gene Therapy Program. To access the list of designated gene therapy products, log in to CignaforHCP.com > Resources > Reimbursement Policies and Payment Policies > Precertification Policies > Cigna Designated Gene Therapy Products Requiring Precertification.

Together, all the way.

Cigna

All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc.

Specialty Medical Injectables			
HCPCS code(s)	**Name**	**Contracted specialty pharmacy**	**Date prior authorization obtained (on or after)**
J2326	SPINRAZA® (nusinersen)	Accredo	May 1, 2018
J0567	BRINEURA®(cerliponase alfa)	Orsini Pharmaceutical Services	March 1, 2020
C9399, J3490	GIVLAARI® (givosiran)	Accredo, PANTHERx	March 1, 2020
J0180	Fabrazyme® (agalsidase beta)[2]	Accredo	September 1, 2020
J2840	KANUMA® (sebelipase alfa)[2]	Accredo	September 1, 2020
J0202	LEMTRADA® (alemtuzumab)[2]	Accredo	September 1, 2020
J0221	Lumizyme® (alglucosidase alfa)[2]	Accredo	September 1, 2020
J0222	ONPATTRO® (patisiran)[2]	Orsini Pharmaceutical Services	September 1, 2020
J1300	SOLIRIS® (eculizumab)[2]	Accredo	September 1, 2020
C9399, J3490, J3590, J9999	TEPEZZA™ (teprotumumab-trbw)[2]	Accredo	September 1, 2020
J1303	ULTOMIRIS® (ravulizumab-cwvz)[2]	Accredo	September 1, 2020
C9399, J3490, J3590, J9999	VYONDYS 53® (golodirsen)[2]	Orsini Pharmaceutical Services	September 1, 2020

2. Cigna may grant an exception to reimburse a one-time, or single, administration of a specialty medical injectable billed by a facility when a customer needs access to the injectable before it can be obtained from a specialty pharmacy with which Cigna has a reimbursement arrangement. The reimbursement restriction may apply when these specialty drugs are administered in a high-intensity setting, such as an outpatient hospital.

Together, all the way.



All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc.

Oncology Injectables[3]			
HCPCS code(s)	**Name**	**Contracted specialty pharmacy**	**Date prior authorization obtained (on or after)**
C9399, J3490, J3590, J9999	ENHERTU® (trastuzumab deruxtecan)[4]	Accredo	September 1, 2020
J9299	OPDIVO® (nivolumab)[4]	Accredo	September 1, 2020
J9228	YERVOY® (ipilimumab)[4]	Accredo	September 1, 2020

3. When prescribing oncology drugs for your patients with Cigna coverage, please request prior authorization, when it's needed, through eviCore healthcare. To access the full list of drugs requiring prior authorization, log in to CignaforHCP.com > Resources > Reimbursement Policies and Payment Policies > Precertification Policies > Oncology Drugs Requiring Precertification through eviCore Healthcare.

4. Cigna may grant an exception to reimburse a one-time, or single, administration of an oncology injectable billed by a facility when a customer needs access to the injectable before it can be obtained from a specialty pharmacy with which Cigna has a reimbursement arrangement. The reimbursement restriction may apply when these oncology drugs are administered in a high-intensity setting, such as an outpatient hospital.

Together, all the way.

Cigna

All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc.